Short Interest in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Drops By 50.0%

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the recipient of a large drop in short interest during the month of July. As of July 15th, there was short interest totaling 22,521 shares, a drop of 50.0% from the June 30th total of 45,019 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 33,926 shares, the days-to-cover ratio is presently 0.7 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, China SXT Pharmaceuticals currently has an average rating of “Sell”.

China SXT Pharmaceuticals Stock Up 24.8%

SXTC opened at $0.07 on Thursday. China SXT Pharmaceuticals has a 52 week low of $0.05 and a 52 week high of $1,046.98. The business has a 50 day moving average price of $1.94 and a two-hundred day moving average price of $3.38. The company has a quick ratio of 7.76, a current ratio of 7.94 and a debt-to-equity ratio of 0.02.

China SXT Pharmaceuticals (NASDAQ:SXTC) last announced its earnings results on Wednesday, July 1st. The company reported ($0.07) earnings per share for the quarter. The business had revenue of $0.26 million during the quarter.

Hedge Funds Weigh In On China SXT Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. XTX Topco Ltd purchased a new position in China SXT Pharmaceuticals during the 4th quarter worth $36,000. Virtu Financial LLC boosted its holdings in shares of China SXT Pharmaceuticals by 107.5% in the third quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after acquiring an additional 15,013 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of China SXT Pharmaceuticals in the third quarter valued at about $78,000. 5.02% of the stock is owned by institutional investors and hedge funds.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.